Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | FABP3 | P05413 | 3/20 | 0.38 |
| ▸ | FABP4 | P15090 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 6/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.35 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.35 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.35 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CMKLR1 | Q99788 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132017 | 1.00 | PTGS2 (0.42) | PTGS2FABP3FABP4FAAHPDE7A | |
| SCHEMBL1131830 | 0.86 | PTPN1 (0.46) | FABP3FABP4ALDH1A1CMKLR1 | |
| SCHEMBL1131834 | 0.86 | PTPN1 (0.46) | FABP3FABP4ALDH1A1CMKLR1 | |
| SCHEMBL1131611 | 0.85 | PTGS2 (0.43) | PTGS2FABP3FABP4PDE7AKCNJ6 | |
| SCHEMBL5861842 | 0.85 | PTGS2 (0.43) | PTGS2FABP3FABP4PDE7AKCNJ6 | |
| SCHEMBL1131371 | 0.81 | FAAH (0.37) | PTGS2FABP3FABP4FAAHKCNJ6 | |
| SCHEMBL1131367 | 0.81 | FAAH (0.37) | PTGS2FABP3FABP4FAAHKCNJ6 | |
| SCHEMBL1132056 | 0.78 | FAAH (0.37) | FABP3FABP4FAAHCMKLR1 | |
| SCHEMBL1132015 | 0.77 | MEN1 (0.37) | FAAHALDH1A1MAPK1 | |
| SCHEMBL1132013 | 0.77 | MEN1 (0.37) | FAAHALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | disclosed |